Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments: 2023-2024

Historic Change in Acquisitions & Divestments for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2024 value amounting to $258.0 million.

  • ARS Pharmaceuticals' Change in Acquisitions & Divestments rose 45.08% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 19.12%. This contributed to the annual value of $258.0 million for FY2024, which is 39.46% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Change in Acquisitions & Divestments is $258.0 million, which was up 39.46% from $185.0 million recorded in FY2023.
  • ARS Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $258.0 million during FY2024, with a 5-year trough of $185.0 million in FY2023.
  • In the last 2 years, ARS Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $221.5 million in 2023 and averaged $221.5 million.
  • Data for ARS Pharmaceuticals' Change in Acquisitions & Divestments shows a peak YoY spiked of 39.46% (in 2024) over the last 5 years.
  • ARS Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $185.0 million in 2023, then spiked by 39.46% to $258.0 million in 2024.